Patents Issued in June 12, 2007
-
Patent number: 7229594Abstract: The invention provides a device for dispensing accurately-controlled small quantities of at least one liquid, comprising a liquid supply (L); a gas supply (G), arranged to selectively supply a gas pressure; and a capillary duct (20) adapted to be filled with liquid to be dispensed, and to eject the liquid. The device has a filling configuration wherein liquid from the supply is in contact with an end (20a) of the capillary duct to fill the capillary duct with liquid; and a liquid separation and ejection configuration, in which liquid remaining in the liquid supply is separated from liquid that fills the capillary duct to form a discrete quantity (V) of liquid filling the capillary duct (20) out of contact with the remaining liquid of the liquid supply. The capillary duct, filled with this discrete quantity (V) of liquid then has one end in contact with the gas supply and another end in contact with the atmosphere.Type: GrantFiled: April 3, 2001Date of Patent: June 12, 2007Assignee: Parabol Technologies S.A.Inventors: Philippe Renaud, Alain Donzel
-
Patent number: 7229595Abstract: This relates to filter columns for isolating nucleic acids. The filter column is adapted for stable placement within the upper portion of standard plastic collection tubes of various sizes. The body of the filter column has a number of surfaces to accommodate placement within variously sized collection tubes. The filter column contains nucleic acid-specific filter which can be located at alternate regions within the filter column, providing different filter surface areas and loading volume capacities using the same column body. The filter column has an opening on an upper end adapted to be sealed by a cap. A method for recovering nucleic acids using such filter column is also provided.Type: GrantFiled: June 15, 2001Date of Patent: June 12, 2007Assignee: Molecular Devices CorporationInventors: Derrick A. Richardson, Derek S. Pai, Jorge Monteon
-
Patent number: 7229596Abstract: The Rh content by percentage in an HC absorbent catalytic converter provided in an exhaust pipe is greater than the Rh content by percentage in an upstream three-way catalyst. In this way, even when HC which has been temporarily absorbed is emitted in an atmosphere and the exhaust gas becomes rich, the HC absorbent catalytic converter displays improved oxidization and removal of HC due to the high content by percentage of Rh which has a high HC conversion ratio in rich atmospheres. There is no necessity to control the air-fuel ratio to a strongly lean ratio and so HC removal can be improved while maintaining suppression of NOx emissions.Type: GrantFiled: August 30, 2001Date of Patent: June 12, 2007Assignee: Nissan Motor Co., Ltd.Inventors: Hidetoshi Ito, Kimiyoshi Nishizawa, Ritsuo Sato
-
Patent number: 7229597Abstract: Provided is an emission treatment system and method for simultaneously remediating the nitrogen oxides (NOx), particulate matter, and gaseous hydrocarbons present in diesel engine exhaust streams. The emission treatment system has an oxidation catalyst upstream of a soot filter coated with a material effective in the Selective Catalytic Reduction (SCR) of NOx by a reductant, e.g., ammonia. Also provided is a method for disposing an SCR catalyst composition on a wall flow monolith that provides adequate catalyst loading, but does not result in unsuitable back pressures in the exhaust.Type: GrantFiled: August 5, 2003Date of Patent: June 12, 2007Assignee: BASFD Catalysts LLCInventors: Joseph Allan Patchett, Joseph Charles Dettling, Elizabeth Alina Przybylski
-
Patent number: 7229598Abstract: A honeycomb body, which is composed in such a manner that a strip of corrugated foil made of heat-resistant stainless steel containing aluminum and a strip of flat foil made of stainless steel are alternately wound or laminated on each other, is incorporated into an outer cylinder made of metal and integrated into one body by means of diffusion bonding, so that a diffusion bonded metallic catalyst carrier can be formed. Surface roughness of the strip of foil after the completion of diffusion bonding is 0.001 to 2.0 ?m when it is expressed by center line average height Ra, and no sintered bridges are formed at both end portions of the diffusion bonded section in the longitudinal direction. The catalyst carrier is manufactured in a condition so that ?b, which is defined by ?b=6.Type: GrantFiled: April 23, 2004Date of Patent: June 12, 2007Assignee: Nippon Steel CorporationInventors: Yasuo Takahashi, Tadayuki Otani, Kazutoshi Iwami, Masayuki Kasuya
-
Patent number: 7229599Abstract: A container for holding powdered reagents that interact with water to form an anti-microbial fluid for use in an apparatus for cleaning and microbially deactivating items. The container includes a fluid inlet connectable to a source of water on an apparatus for cleaning and microbially deactivating items and a fluid outlet in fluid communication with items to be microbially deactivated. A continuous fluid passage is defined through the container between the fluid inlet and the fluid outlet. A plurality of spaced-apart barrier elements are disposed within the fluid passage to define a plurality of isolated compartments within the container. The barrier elements are impervious to powdered reagents, but permeable to the chemical reagents when dissolved in a liquid. A first dry, powdered reagent is disposed within one of the compartments for forming an anti-microbial solution when water flows through the container.Type: GrantFiled: August 1, 2003Date of Patent: June 12, 2007Assignee: Steris Inc.Inventors: Jeffrey R. Horacek, Christopher A. Jethrow
-
Patent number: 7229600Abstract: Rare earth compositions comprising nanoparticles, methods of making nanoparticles, and methods of using nanoparticles are described. The compositions of the nanomaterials discussed may include scandium (Sc), yttrium (Y), lanthanum (La), cerium (Ce), praseodymium (Pr), neodymium (Nd), promethium (Pm), samarium (Sm), europium (Eu), gadolinium (Gd), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er), thulium (Tm), ytterbium (Yb), and lutetium (Lu). The nanoparticles can be used to make organometallics, nitrates, and hydroxides. The nanoparticles can be used in a variety of applications, such as pigments, catalysts, polishing agents, coatings, electroceramics, catalysts, optics, phosphors, and detectors.Type: GrantFiled: December 4, 2003Date of Patent: June 12, 2007Assignee: NanoProducts CorporationInventor: Tapesh Yadav
-
Patent number: 7229601Abstract: A process for reclaiming ammonia from waste streams comprises reacting at least one waste stream with an excess of hydroxide to produce ammonia and water. The ammonia is removed from the reaction vessel and purified.Type: GrantFiled: February 6, 2004Date of Patent: June 12, 2007Assignee: SEH-America, Inc.Inventor: Brian L. Tansy
-
Patent number: 7229602Abstract: A method of preparing metal chalcogenide particles. The method comprising the step of reacting an amine and metal complex precursors. The metal complex precursors comprising a chalcogenide and an electrophilic group. The reaction forming metal chalcogenide particles substantially free of the electrophilic group.Type: GrantFiled: June 4, 2004Date of Patent: June 12, 2007Assignee: National University of SingaporeInventors: Wee Shong Chin, Zhihua Zhang, Wen Pei Lim
-
Patent number: 7229603Abstract: A novel method is set out of preparation of radioactive diagnostic radiopharmaceutical in a stable, shippable, lyophilized form by an apparatus designed to rapidly flash freeze and dehydrate a radiopharmaceutical composition to minimize auto radiolysis. The method proposes rapid cooling and removal of ambient vapor, and then ultra cold removal when the potential of explosive liquid oxygen is eliminated. The radioactive diagnostic radiopharmaceutical requires no further cold or refrigerated storage, including with respect to shipping, subsequent to stabilization. The preferred composition can be reconstituted “on site” by the addition of a suitable diluent to bring the radiopharmaceutical complex into solution at a desired concentration.Type: GrantFiled: October 22, 2004Date of Patent: June 12, 2007Assignee: AnazaoHealth CorporationInventors: John H. Kuperus, Robert G. McKenzie, Jr., Brooke Schumm, III
-
Patent number: 7229604Abstract: The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.Type: GrantFiled: September 26, 2003Date of Patent: June 12, 2007Assignee: Board of Regents, The University of Texas SystemInventors: David J. Yang, Chun W. Liu, Dong-Fang Yu, E. Edmund Kim
-
Patent number: 7229605Abstract: Methods for determining the effect of a Clostridial neurotoxin on muscle are disclosed. In particular, methods for determining a potency and/or diffusion of a neurotoxin based on a nuclear index and/or an amount of muscle atrophy are disclosed. The methods may be used to distinguish two different Clostridial neurotoxins. In certain embodiments, the neurotoxins are obtained from Clostridium botulinum.Type: GrantFiled: August 13, 2004Date of Patent: June 12, 2007Assignee: Allergan, Inc.Inventors: James M. Holland, Edward Chow
-
Patent number: 7229606Abstract: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.Type: GrantFiled: January 12, 2004Date of Patent: June 12, 2007Assignee: Epix Pharmaceuticals, Inc.Inventors: Thomas J. McMurry, Hironao Sijiki, Daniel M. Scott, Randall B. Lauffer
-
Patent number: 7229607Abstract: A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.Type: GrantFiled: October 7, 2002Date of Patent: June 12, 2007Assignee: Sosei R&D LtdInventors: Robin Mark Bannister, Andrew John McGlashan Richards, Julian Clive Gilbert, David A. V. Morton, John Staniforth
-
Diarylbutadiene-substituted methyltrialkylsilanes and photoprotective compositions comprised thereof
Patent number: 7229609Abstract: Novel 4,4-diarylbutadiene-substituted methyltrialkylsilanes having the structural formula (I): are useful sunscreens for UV-photoprotecting human skin against the damaging effects of UV-radiation, notably UV-A radiation.Type: GrantFiled: November 24, 2004Date of Patent: June 12, 2007Assignee: L'OrealInventor: Herve Richard -
Diarylbutadiene-substituted diorganopolysiloxanes and photoprotective compositions comprised thereof
Patent number: 7229610Abstract: Novel 4,4-diarylbutadiene-substituted diorganopolysiloxanes having the structural formulae (1) or (2): in which A is a radical of formula (3) below: are useful sunscreens for UV-photoprotecting human skin against the damaging effects of UV-radiation, notably UV-A radiation.Type: GrantFiled: November 24, 2004Date of Patent: June 12, 2007Assignee: L'OrealInventor: Herve Richard -
Patent number: 7229611Abstract: Disclosed are clear antiperspirant or deodorant compositions that include visible capsules.Type: GrantFiled: August 1, 2003Date of Patent: June 12, 2007Assignee: The Gillette CompanyInventors: Jose F. Zamudio-Tena, Gordon G. Guay, Tuan M. Vu, John Anderson
-
Patent number: 7229612Abstract: The present invention related to compositions (deodorizing or not) for human and animal excrement, especially pest and livestock, comprised of acidic agents and water soluble polymers, wherein the acidic agents are base neutralizers for the ammonia and indolic amines in the excrement and the water soluble polymers are barrier forming agents for the vapor of the offensive odor producing compounds in the excrement and for slowing down the air oxidative and enzymatic nitrification of the excrement ammonia and organic nitrogen thus dispersing the attenuating nitrate concentrations in the environment. The present invention further relates to a method of applying said compositions to excrement. Said compositions may be applied to excrement in liquid form by mixing the liquid composition together with the excrement, or in the form of a spray, by spraying the composition directly onto the excrement.Type: GrantFiled: March 4, 2002Date of Patent: June 12, 2007Assignee: Damar Holdings S.A.Inventors: Shalom Levi, Steve Daren
-
Patent number: 7229613Abstract: A method for treating hyperglycemia and/or reducing serum glucose levels in a patient that includes administering to the patient a therapeutically effective amount of an amine polymer is disclosed. In one embodiment, the amine polymer is aliphatic. Examples of polymers useful in an embodiment of the invention include sevelamer hydrogen chloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula: and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that lowers serum glucose.Type: GrantFiled: April 17, 2002Date of Patent: June 12, 2007Assignee: Genzyme CorporationInventors: Steven K. Burke, Joanne M. Donovan
-
Patent number: 7229614Abstract: The present invention is directed to methods of treating or preventing angiomyolipomas by administering interferon gamma. It also encompasses methods for assessing the risk of a patient developing angiomyolipomas based upon interferon gamma expression.Type: GrantFiled: July 1, 2003Date of Patent: June 12, 2007Assignee: The Brigham and Women's Hospital, Inc.Inventors: Sandra L. Dabora, David J. Kwiatkowski
-
Patent number: 7229615Abstract: A vaccine for in ovo vaccination against avian coccidiosis produced by a method including obtaining the coccidial oocysts from a fecal suspension, homogenizing the fecal suspension, separating the oocysts from the fecal debris by either salt flotation using sodium sulfate or gas flotation using air, sporulating the oocysts using hydrogen peroxide and air sparging, bleaching the sporulated oocysts, washing the bleached oocysts, concentrating the sterile washed oocysts and combining the concentrates of various species of coccidial oocysts, and producing a vaccine. The method in whole or in part can be applied to other kinds of encysted protozoa to produce vaccines for various types of animals.Type: GrantFiled: October 12, 2005Date of Patent: June 12, 2007Assignee: Pfizer, Inc.Inventors: Harold N. Conkle, Joseph E. Schultz, Scott J. Blonigen, Fred H. Weber, David R. Kilanowski, Bruce Monzyk, Timothy M. Werner, Chad M. Cucksey, Hamish A. I. McArthur, Ted L. Tewksbury
-
Patent number: 7229616Abstract: The present invention relates to the use of a supernatant of lactic acid bacteria or of Bifidobacteria capable of preventing colonization of intestinal cells by Giardia intestinalis, for the preparation of an ingestible carrier for the treatment and/or prophylaxis of disorders associated with the colonization of the gut by Giardia intestinalis. The present invention also pertains to specific strains of Bifidobacterium having the above traits and to the ingestible carrier, such as a food or pharmaceutical composition, containing such supernatant or the microorganisms.Type: GrantFiled: April 20, 2005Date of Patent: June 12, 2007Assignee: Nestec S.A.Inventors: Eduardo Schiffrin, Pablo Perez
-
Patent number: 7229617Abstract: Anti-DR4 or Anti-DR5 antibody agonists, combined with apoptosis-inducing agents, synergistically induce apoptosis in cancer cells.Type: GrantFiled: November 25, 2003Date of Patent: June 12, 2007Assignee: IRM LLCInventors: Marc Nasoff, Quinn L. Deveraux, Deborah A. Knee, Pedro Aza-Blanc, Garret M. Hampton, Klaus Wagner
-
Patent number: 7229618Abstract: The present invention provides crystalline forms and three-dimensional atomic structure coordinates of Synagis Fab. The present invention further provides methods of using such three-dimensional atomic structure coordinates for designing and identifying Synagis binding agents. The present invention also provides machine readable media embedded with the three-dimensional atomic structure coordinates of Synagis Fab and methods of using them.Type: GrantFiled: August 17, 2005Date of Patent: June 12, 2007Assignees: Medimmune, Inc., Bowie State UniversityInventors: Leslie S. Johnson, Bradford Braden
-
Patent number: 7229619Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: GrantFiled: November 28, 2000Date of Patent: June 12, 2007Assignee: MedImmune, Inc.Inventors: James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffrey D. Watkins, Herren Wu
-
Patent number: 7229620Abstract: Methods and kits for radiolabeling proteins, peptides and ligands with radiolytic isotopes, particularly yttrium-90, are disclosed, whereby sufficient purity, specific activity and binding affinity are achieved such that the radiolabeled protein may be directly administered to a patient without further column purification. Such kits and methods will be particularly useful in bringing radioimmunotherapy to the hospital and outpatient setting for the treatment of cancer.Type: GrantFiled: July 15, 2005Date of Patent: June 12, 2007Assignee: Biogen Idec Inc.Inventor: Paul Chinn
-
Patent number: 7229621Abstract: The present invention is related to a method for enhancing the immunogenicity of an antigen in a mammal by introducing into the mammal an antigen or a portion thereof and administering to the mammal a treatment that increases antigen presentation in a lymphoid organ.Type: GrantFiled: March 15, 2001Date of Patent: June 12, 2007Assignee: Torrey Pines Institute for Molecular StudiesInventor: Carol O. Cowing
-
Patent number: 7229622Abstract: The present invention provides synthetic chimeric fimbrin peptides which induce an immunogenic response in animals to non-typable Haemophilus influenzae and that do not require tedious purification techniques. The synthetic chimeric fimbrin peptides reduce the severity of otitis media caused by Haemophilus influenzae. The synthetic chimeric fimbrin peptides are synthesized using commercially available peptide synthesizers. The synthetic chimeric fimbrin peptides comprises three peptide units. The first peptide unit is a subunit of the fimbrin protein. Preferably, the fimbrin subunit is comprised of the amino acids of Sequence ID No. 1 or Sequence ID No. 2. The second peptide unit is a t cell epitope, and preferably has the amino acid sequence of SEQ ID NO. 3. The third peptide unit is a linker peptide unit which joins the first and second peptide unit.Type: GrantFiled: August 19, 2002Date of Patent: June 12, 2007Assignee: The Ohio State University Research FoundationInventors: Lauren O. Bakaletz, Pravin T. P. Kaumaya
-
Patent number: 7229623Abstract: The present invention is generally directed to Her-2/neu fusion proteins, nucleic acid molecules encoding Her-2/neu fusion proteins, viral vectors expressing Her-2/neu fusion proteins, and pharmaceutical compositions (e.g., vaccines) comprising the Her-2/neu fusion proteins and/or nucleic acid molecules encoding the Her-2/neu fusion proteins. The present invention is also directed to methods of treating or preventing cancer by eliciting or enhancing an immune response to the Her-2/neu protein, including for uses in the treatment of malignancies associated with the Her-2/neu oncogene.Type: GrantFiled: August 3, 2000Date of Patent: June 12, 2007Assignee: Corixa CorporationInventors: Martin A. Cheever, Dirk Gheysen
-
Patent number: 7229624Abstract: The invention provides compositions and processes for the production of ordered and repetitive antigen or antigenic determinant arrays. The compositions of the invention are useful for the production of vaccines for the prevention of infectious diseases, the treatment of allergies and the treatment of cancers. Various embodiments of the invention provide for a virus, virus-like particle, viral capsid particle, phage or recombinant form thereof coated with any desired antigen in a highly ordered and repetitive fashion as the result of specific interactions. In one specific embodiment, a versatile new technology based on a cassette-type system (AlphaVaccine Technology) allows production of antigen coated viral particles. Other specific embodiments allow the production of antigen coated hepatitis B virus-like particles or antigen coated Measles virus-like particles.Type: GrantFiled: December 12, 2003Date of Patent: June 12, 2007Assignee: Cytos Biotechnology AGInventors: Wolfgang A. Renner, Frank Hennecke, Lars Nieba, Martin Bachmann
-
Patent number: 7229625Abstract: Non-infectious, retrovirus-like particles contain mutations to reduce gag-dependent RNA-packaging of the gag gene product, eliminate reverse transcriptase activity of the pol gene product, eliminate integrase activity of the pol gene product and eliminate RNase H activity of the pol gene product through genetic manipulation of the gag and pol genes. The corresponding nucleic acid molecules are described. The non-infectious, retrovirus-like particles have utility in in vivo administration including to humans and in diagnosis.Type: GrantFiled: April 22, 2005Date of Patent: June 12, 2007Assignee: Sanofi Pasteur LimitedInventors: Benjamin Rovinski, Shi-Xian Cao, Fei-Long Yao, Roy Persson, Michel H. Klein
-
Patent number: 7229626Abstract: Methods for treating psychiatric disorders include intracranial administration of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin type A, to a human patient.Type: GrantFiled: March 22, 2004Date of Patent: June 12, 2007Assignee: Allergan, Inc.Inventor: Stephen Donovan
-
Patent number: 7229627Abstract: Disclosed are apparatuses and methods for the production of attenuated aseptic parasites in hematophagous insects generally, and production of Plasmodium species sporozoites in Anopheles species mosquitoes specifically; apparatuses and methods for the production of strains of hematophagous insects with desired properties such as hypoallergenicity or hyperinfectivity; methods of producing a parasite strain that is capable of withstanding cyropreservation at temperatures close to freezing; apparatuses and methods for the injection of an attenuated parasite vaccine; production of parasites and hematophagous insects that are free from contamination by unwanted biological agents; apparatuses for the reconstruction of complex parasitic life cycles aseptically to avoid the contamination of the parasite or the insect vector host with unwanted biological agents.Type: GrantFiled: October 4, 2004Date of Patent: June 12, 2007Assignee: Sanaria, Inc.Inventors: Stephen L. Hoffman, Thomas C. Luke
-
Patent number: 7229628Abstract: T cell activation in response to antigen is increased by the administration of binding agents that block CTLA-4 signaling. When CTLA-4 signaling is thus blocked, the T cell response to antigen is released from inhibition. Such an enhanced response is useful for the treatment of tumors, chronic viral infections, and as an adjuvant during immunization.Type: GrantFiled: December 7, 1999Date of Patent: June 12, 2007Assignee: The Regents of the University of California, Office of Technology TransferInventors: James Patrick Allison, Dana R. Leach, Matthew E. Krummel
-
Patent number: 7229629Abstract: Carboxylic-gated-nitroxide (CGN) compounds and their esterified derivatives are discovered and disclosed as compositions and shown to have the potential in treating a variety of acute and chronic diseases and disorders resulting from reactive oxygen species (ROS) injury. Compositions for treating tissue damage from ROS injury containing CGN, or active derivatives thereof, in a suitable pharmaceutical, cosmetic, and diagnostic formulations are described.Type: GrantFiled: September 6, 2002Date of Patent: June 12, 2007Assignee: SynZyme Technologies, LLCInventors: Jen-Chang Hsia, Li Ma
-
Patent number: 7229630Abstract: The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.Type: GrantFiled: June 20, 2003Date of Patent: June 12, 2007Assignee: Novalar Pharmaceuticals, Inc.Inventors: Andrew X. Chen, Julius Knowles, Eckard Weber
-
Patent number: 7229631Abstract: The invention provides oil-in-water emulsions comprising recombinant collagen-like polymer in an amount sufficient to act as stabiliser of the emulsion. The polymer is especially a polypeptide which is free of helix structure, has an isoelectric point at least 0.5 pH units removed from the pH of the oil-in-water emulsion. Furthermore, amphiphilic recombinant collagen-like polymers are provided for use in oil-in-water emulsions. The amphiphilic polymers are polar at one end as a result of a relative abundance of polar amino acids, and apolar at the other end as a result of a relative abundance of apolar amino acids.Type: GrantFiled: September 26, 2003Date of Patent: June 12, 2007Assignee: Fuji Photo Manufacturing Europe B.V.Inventors: Joseph Hubertus Olijve, Jan Bastiaan Bouwstra, Frederik Anton Wolf De, Marc Willem Theodoor Werten, Hendrik Wouter Wisselink, Richéle Deodata Wind, Tanja Jacoba Bosch Van Den, Yuzo Toda
-
Patent number: 7229632Abstract: An emulsion having one oily outer phase, and two aqueous inner phases, one of which is a gel. The emulsion may be used for cosmetic, pharmaceutical, veterinary and detergent purposes.Type: GrantFiled: February 5, 2002Date of Patent: June 12, 2007Assignee: Societe d'Exploitation de Produits pour les Industries Chimiques-SeppicInventors: Chantal Amalric, Alicia Roso, Nelly Michel
-
Patent number: 7229633Abstract: The present invention relates generally to the preparation and use of biological tissue adhesives which rely on combining fibrinogen and thrombin. More particularly, the present invention relates to a method of preparing a fibrin sealant whereby said sealant is formed by reconstituting the fibrinogen or the thrombin component in the presence of biological and/or non-biological agents such as drugs, chemicals, and proteins. Preferably, these agents are introduced in solution, such as for example, a corticosteroid-containing solution like a betamethasone solution containing betamethasone acetate or betamethasone sodium phosphate; a triamicinolone solution; or a methylprednisolone solution. These solutions may be substituted for, or provided as a complement to, other solutions that are typically used in the preparation of fibrin sealants such as, for example, calcium chloride.Type: GrantFiled: December 4, 2004Date of Patent: June 12, 2007Assignee: Spinal Restoration, Inc.Inventors: Sam L. Austin, Thomas E. Davis
-
Patent number: 7229634Abstract: The present invention provides engineered proteins and biomedical products made from the engineered proteins. The biomedical products include lenses useful for ophthalmic purposes.Type: GrantFiled: January 21, 2005Date of Patent: June 12, 2007Assignees: California Institute of Technology, The Regents of the University of CaliforniaInventors: David A. Tirrell, Daniel M. Schwartz, Paul J. Nowatzki, Robert H. Grubbs
-
Patent number: 7229635Abstract: The present invention is directed to a method of modulating the release of at least one endogenous compound in vivo. The method comprises delivering intranasally at least one micro-construct comprising an agonist and a pharmaceutically acceptable carrier to a locus comprising an agonist receptor and a heterologous receptor that is coupled to at least one common signaling molecule. The micro-construct used in the present inventive method provides sustained release of the agonist provided by erosion of an exterior surface defined by the micro-construct. Once released, the agonist effectively up- or down-regulates at least one signaling molecule common to both the agonist receptor and the heterologous receptor, thereby potentiating or desensitizing the heterologous receptor in order to modulate release of at least one endogenous compound under the control of the heterologous receptor.Type: GrantFiled: April 20, 2001Date of Patent: June 12, 2007Assignee: Indiana University Research and Technology CorporationInventor: Michael J. Kubek
-
Patent number: 7229636Abstract: A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.Type: GrantFiled: February 26, 2004Date of Patent: June 12, 2007Assignee: Nastech Pharmaceutical Company Inc.Inventors: Steven C. Quay, Peter C. Aprile, Zenaida O. Go, Anthony P. Sileno
-
Patent number: 7229637Abstract: The invention relates to the food and medical industries, medical cosmetics, dermatology, agriculture and the mixed feed industry. According to the invention vicinal dithioglycole (common formula RCH(SH)CH(SH)R?1 (I)) is used as a food additive, a food product, physiologically-active substances and active ingredients of forage additives and of forage, in cosmetic and/or dermatological and skin-therapeutic remedies. The invention comprises methods for producing such additives, products and remedies. The substance of formula (I) stimulates physiological processes, increases human and animal immunity, inhibits undesirable process in organisms and food products, produces curative and preventive action of skin, hair and nails and after vicinal dithioglycole is administered the intoxication effect of alcohol consumption known as hang-over is completely remored.Type: GrantFiled: December 28, 2000Date of Patent: June 12, 2007Inventors: Sergei Mikhailovich Zenovich, Boris Khaimovich Strelets
-
Patent number: 7229638Abstract: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of a biopolymer.Type: GrantFiled: September 30, 2005Date of Patent: June 12, 2007Assignee: Artemis Proteomics, Ltd.Inventors: George Jackowski, Brad Thatcher, John Marshall, Jason Yantha, Tammy Vrees
-
Patent number: 7229639Abstract: The present invention relates to pharmaceutically acceptable and stable compositions, which are preferably clear transparent, for liquid filling hard shell capsules, hard shell capsules containing these compositions, and a process for preparing these hard shell capsules and whereby the shells of said hard capsules are preferably clear transparent.Type: GrantFiled: March 7, 2003Date of Patent: June 12, 2007Assignee: Warner-Lambert CompanyInventors: Emmanuelle Mireille Guillard, Nicolas Madit, Robert Anthony Scott
-
Patent number: 7229640Abstract: A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxtine.Type: GrantFiled: December 18, 2001Date of Patent: June 12, 2007Assignee: SmithKline Beecham p.l.c.Inventors: Graham Stanley Leonard, David Philip Elder
-
Patent number: 7229641Abstract: A novel rapid-melt composition, including methods of making the same, and methods of using the same for the delivery of prophylactic and therapeutic active materials to a mammal. The rapid-melt compositions are formed by molding or compression, with an additional heating step being preferred.Type: GrantFiled: August 1, 2002Date of Patent: June 12, 2007Assignee: Capricorn Pharma, Inc.Inventor: S. Rao Cherukuri
-
Patent number: 7229642Abstract: Disclosed herein is a oral extended release dosage form comprising a plurality of granules of an effective amount of a pharmaceutically active compound, at least one amino acid, and an intragranular polymer in which the granule is dispersed within a hydrophilic extragranular polymer matrix which is more rapidly hydrating than the intragranular polymer. The amino acid is selected for hydropathy characteristics depending on solubility characteristics of the active compound.Type: GrantFiled: June 22, 2005Date of Patent: June 12, 2007Assignee: Scolr, Inc.Inventors: A. Reza Fassihi, Thomas Dürig
-
Patent number: 7229643Abstract: The invention provides a pharmaceutically elegant solid oral formulation of olanzapine and a process for making such formulation.Type: GrantFiled: July 8, 2004Date of Patent: June 12, 2007Assignee: Eli Lilly and CompanyInventors: George Randall Cochran, Tommy Clifford Morris
-
Patent number: 7229644Abstract: The present invention is related to compositions of modafinil, including compositions of modafinil and one or more diluents, disintegrants, binders and lubricants, and the processes for their preparation thereof.Type: GrantFiled: September 13, 2002Date of Patent: June 12, 2007Assignee: Cephalon, Inc.Inventors: Vincent Corvari, George Grandolfi, Alpa Parikh